The Food and Drug Administration today revoked the emergency use authorization that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, FDA said that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use. For more details, see the FDA news release.

Related News Articles

Blog
The Centers for Medicare & Medicaid Services recently announced that Medicare will not continue to cover audio-only telehealth visits when the COVID-19…
Headline
The Centers for Medicare & Medicaid Services today released a second final notice of benefit and payment parameters to implement standards governing health…
Headline
The Centers for Medicare & Medicaid Services Office of Minority Health will host a May 13 webinar on building COVID-19 vaccine confidence. Register for the…
Headline
The Food and Drug Administration today updated its webpage on the performance of SARS-CoV-2 serology tests authorized for emergency use to help health…
Headline
 A Centers for Disease Control and Prevention assessment affirms the ability of the two authorized mRNA COVID-19 vaccines to prevent hospitalization…
Headline
The Centers for Disease Control and Prevention today announced relaxed guidance for mask wearing, stating that individuals fully vaccinated against COVID-19 no…